Citations

Clear

861 citation(s) found for "Sd, Wexner".

The Association between Exposures and Disease Characteristics in Familial Pulmonary Fibrosis
Copeland, Carla R. , Donnelly, Edwin F. , Mehrad, Mitra , Ding, Guixiao, Markin, Cheryl, Douglas, Katrina, Wu, Pingsheng , Cogan, Joy D. , Young, Lisa R. , Bartholmai, Brian J. , Flaherty, Kevin R. , Lancaster, Lisa , Flaherty, Kevin R , Loyd, James E , Kropski, Jonathan A , Salisbury, Margaret L , Bartholmai, Brian J , Martínez, Fernando J. , Loyd, James E. , Blackwell, Timothy S

Mayo Clinic

Annals of the American Thoracic Society | July 25, 2022 | Volume: 19 | Issue: 12 | Pages: 2003-2012

10.1513/annalsats.202203-267oc | PMID 35877079 Get It

Abstract Rationale Heterogeneous characteristics are observed in familial pulmonary fibrosis (FPF), suggesting that nongenetic factors contribute to disease manifestations. Objectives To determine the relationship between environmental exposures and disease characteristics of FPF, including the morphological characteristics on chest computed tomography (CT) scan, and timing of FPF symptom onset, lung transplantation, or death. Methods Subjects with FPF with an exposure questionnaire and chest CT were selected from a prospective cohort at Vanderbilt. Disease characteristics were defined by lung parenchymal findings on chest CT associated with fibrotic hypersensitivity pneumonitis (fHP) or usual interstitial pneumonia (UIP) and by time from birth to symptom onset or a composite of lung transplantation or death. After assessing the potential for confounding by sex or smoking, adjusted logistic or Cox proportional hazards regression models identified exposures associated with fHP or UIP CT findings. Findings were validated in a cohort of patients with sporadic pulmonary fibrosis enrolled in the LTRC (Lung Tissue Research Consortium) study. Results Among 159 subjects with FPF, 98 (61.6%) were males and 96 (60.4%) were ever-smokers. Males were less likely to have CT features of fHP, including mosaic attenuation (FPF: adjusted [for sex and smoking] odds ratio [aOR], 0.27; 95% confidence interval [CI], 0.09–0.76; P = 0.01; LTRC: aOR, 0.35; 95% CI, 0.21–0.61; P = 0.0002). Organic exposures, however, were not consistently associated with fHP features in either cohort. Smoking was a risk factor for honeycombing in both cohorts (FPF: aOR, 2.19; 95% CI, 1.12–4.28; P = 0.02; LTRC: aOR, 1.69; 95% CI, 1.22–2.33; P = 0.002). Rock dust exposure may also be associated with honeycombing, although the association was not statistically-significant when accounting for sex and smoking (FPF: aOR, 2.27; 95% CI, 0.997–5.15; P = 0.051; LTRC: aOR, 1.51; 95% CI, 0.97–2.33; P = 0.07). In the FPF cohort, ever-smokers experienced a shorter transplant-free survival (adjusted hazard ratio, 1.64; 95% CI, 1.07–2.52; P = 0.02), whereas sex was not associated with differential survival (male adjusted hazard ratio, 0.75; 95% CI, 0.50–1.14; P = 0.18). Conclusions In FPF, smoking contributes to shortened transplant-free survival and development of honeycombing, a finding that is also likely applicable to sporadic pulmonary fibrosis. Females are more likely to manifest CT features of fHP (mosaic attenuation), a finding that was incompletely explained by sex differences in exposures. These findings may have implications for pulmonary fibrosis classification and management.
Cultivating Clinical Clarity through Computer Vision: A Current Perspective on Whole Slide Imaging and Artificial Intelligence
Patel, Ankush , Mohanty, Sambit K. , Sharma, Shivani , Gangal, Shivam, Eloy, Catarina , Patel, Ankush U, Eloy, Catarina , Patel, Ankush U , Shaker, Nada , Parwani, Anil Vasdev

Mayo Clinic

Diagnostics | July 22, 2022 | Volume: 12 | Issue: 8 | Pages: 1778

10.3390/diagnostics12081778 | PMID 35892487 Get It

Diagnostic devices, methodological approaches, and traditional constructs of clinical pathology practice, cultivated throughout centuries, have transformed radically in the wake of explosive technological growth and other, e.g., environmental, catalysts of change. Ushered into the fray of modern laboratory medicine are digital imaging devices and machine-learning (ML) software fashioned to mitigate challenges, e.g., practitioner shortage while preparing clinicians for emerging interconnectivity of environments and diagnostic information in the era of big data. As computer vision shapes new constructs for the modern world and intertwines with clinical medicine, cultivating clarity of our new terrain through examining the trajectory and current scope of computational pathology and its pertinence to clinical practice is vital. Through review of numerous studies, we find developmental efforts for ML migrating from research to standardized clinical frameworks while overcoming obstacles that have formerly curtailed adoption of these tools, e.g., generalizability, data availability, and user-friendly accessibility. Groundbreaking validatory efforts have facilitated the clinical deployment of ML tools demonstrating the capacity to effectively aid in distinguishing tumor subtype and grade, classify early vs. advanced cancer stages, and assist in quality control and primary diagnosis applications. Case studies have demonstrated the benefits of streamlined, digitized workflows for practitioners alleviated by decreased burdens.
Applicants’ Perspectives on Virtual vs In-person Colorectal Residency Interviews
Jabri, Ali Al, D’Angelo, Anne-Lise D. , Kelley, Scott R. , D'Angelo, Jonathan D, D'Angelo, Anne-Lise D, Abelson, Jonathan S. , D’Angelo, Jonathan D. , Husain, Syed

Mayo Clinic

Diseases of the Colon & Rectum | July 19, 2022 | Volume: 65 | Issue: 10 | Pages: 1162-1166

10.1097/dcr.0000000000002545 | PMID 35853182 Get It

A 44‐year‐old man with esophageal ulcer
Fogwe, Delvise T. , Ho, Matthew T., Shah, Aditya , Shah, Aditya S

Mayo Clinic

Clinical Case Reports | July 18, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/ccr3.6044 | PMID 35865767 Get It

Exposure to radon and heavy particulate pollution and incidence of brain tumors
Prasad, Rahul N. , Cioffi, Gino , Kruchtko, Carol, Trifiletti, Daniel M. , Gondi, Vinai , Brown, Paul D. , Perlow, Haley K. , Mishra, Mark V. , Chakravarti, Arnab , Ostrom, Quinn T. , Palmer, Joshua D , Cioffi, Gino , Trifiletti, Daniel M , Mishra, Mark V , Perlow, Haley K , Chakravarti, Arnab , Ostrom, Quinn T , Palmer, Joshua D. , Zaorsky, Nicholas G. , Barnholtz‐Sloan, Jill S.

Mayo Clinic

Neuro-Oncology | June 28, 2022 | Volume: 25 | Issue: 2 | Pages: 407-417

10.1093/neuonc/noac163 | PMID 35762336 Get It

Abstract Background Global incidence for brain tumors varies substantially without explanation. Studies correlating radon exposure and incidence are inconclusive. Particulate pollution has been linked to increased tumor incidence. Particulates may disrupt the blood-brain barrier allowing intracranial exposure to oncogenic radon. We investigated the relationship between exposure to residential radon, particulate pollution, and brain tumor incidence in the United States (US). Methods County-level median radon testing results and annual air quality index values were obtained and divided into tertiles. Counties without both values were excluded. Four groups of counties were generated: high particulate/high radon (high/high), high/low, low/high, and low/low. Using incidence data from the Central Brain Tumor Registry of the US (provided by CDC’s National Program of Cancer Registries and NCI’s SEER), annual age-adjusted incidence rates (AAAIRs) by group were generated by behavior. Incidence rate ratios were calculated to examine for significant differences (α = .05). Poisson regression accounting for possible confounders was conducted. Results Counties with available data included 83% of the US population. High/high exposure was significantly associated with increased AAAIR of all non-malignant tumors (up to 26% higher, including most meningiomas) even after accounting for potential confounders. An increased AAAIR was noted for all malignant tumors (up to 10% higher), including glioblastoma, but was negated after accounting for demographic/socioeconomic differences. Conclusions We present the first report suggesting increased non-malignant brain tumor incidence in regions with high particulate and radon exposure. These findings provide insight into unexplained variation in tumor incidence. Future studies are needed to validate these findings in other populations.
Ulcerative Wound in a Patient with Ulcerative Colitis
Fogwe, Delvise T. , Tawileh, Raya Abu, Aditya, Shah

Mayo Clinic

No container title available | June 27, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.165631150.07318544/v1 Get It

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Thompson, Kevin J. , Leon‐Ferre, Roberto A. , Zahrieh, David , Metzger, Filho Otto, Sikov, William M. , Liu, Minetta C. , Carter, Jodi M. , Klee, Eric W. , Weinshilboum, Richard M. , Wang, Liewei , Zahrieh, David M. , Ingle, James N. , Goetz, Matthew P , Kalari, Krishna R , Thompson, Kevin J , Carter, Jodi , Sinnwell, Jason P. , Suman, Vera J. , Asad, Sarah , Stover, Daniel G. , Carey, Lisa A. , Weinshilboum, Richard M. , Boughey, Judy C. , Couch, Fergus J. , Goetz, Matthew P. , Kalari, Krishna R.

Mayo Clinic

NAR Cancer | June 17, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/narcan/zcac018 | PMID 35734391 Get It

Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor (LAR) is the most consistently identified TNBC subtype, but the clinical utility has yet to be established. Here, we constructed a novel genomic classifier, LAR-Sig, that distinguishes the LAR subtype from other TNBC subtypes and provide evidence that it is a clinically distinct disease. A meta-analysis of seven TNBC datasets (n = 1086 samples) from neoadjuvant clinical trials demonstrated that LAR patients have significantly reduced response (pCR) rates than non-LAR TNBC patients (odds ratio = 2.11, 95% CI: 1.33, 2.89). Moreover, deconvolution of the tumor microenvironment confirmed an enrichment of luminal epithelium corresponding with a decrease in basal and myoepithelium in LAR TNBC tumors. Increased immunosuppression in LAR patients may lead to a decreased presence of cycling T-cells and plasma cells. While, an increased presence of myofibroblast-like cancer-associated cells may impede drug delivery and treatment. In summary, the lower levels of tumor infiltrating lymphocytes (TILs), reduced immune activity in the micro-environment, and lower pCR rates after NAC, suggest that new therapeutic strategies for the LAR TNBC subtype need to be developed.
Characterizing mechanism-based pain phenotypes in patients with chronic pancreatitis: a cross-sectional analysis of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
Saloman, Jami L. , Conwell, Darwin L. , Fogel, Evan L. , Vege, Santhi Swaroop , Li, Liang , Andersen, Dana K. , Fisher, William E., Forsmark, Christopher E., Hart, Phil A. , Park, Walter G. , Topazian, Mark , Yadav, Dhiraj , Saloman, Jami L , Li, Shuang , Pandol, Stephen J. , Phillips, Anna Evans , Van Den Eeden, Stephen K , Serrano, José

Mayo Clinic

Pain | June 8, 2022 | Volume: 164 | Issue: 2 | Pages: 375-384

10.1097/j.pain.0000000000002710 | PMID 36149018 Get It

Abstract Pain is common in chronic pancreatitis (CP) and profoundly reduces quality of life (QoL). Multiple underlying mechanisms contribute to a heterogenous pain experience and reduce efficacy of pain management. This study was designed to characterize the distribution of mechanism-based pain phenotypes in painful CP. The data analyzed were collected as part of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies, an NCI/NIDDK-funded longitudinal study of the natural history of CP. The PROspective Evaluation of Chronic pancreatitis for EpidEmiologic and translational stuDies includes patient-reported outcome (PRO) measures of pain, medication use, global health, and QoL. Of subjects (N = 681) with CP, 80% experienced abdominal pain within the year before enrollment. Subjects who experienced pain in the week before enrollment (N = 391) completed PROMIS Neuropathic and Nociceptive Pain Quality instruments which were then used to classify them by pain type: 40% had nociceptive, 5% had neuropathic-like, and 32% had both types of pain. The prevalence of having both types of pain was higher among women and subjects with diabetes mellitus, whereas nociceptive-only pain was more prevalent among men and those with pancreatic duct stricture. Other factors, including pain medication use and healthcare utilization, did not differ between groups based on pain type. Subjects in the Both group had significantly worse health and QoL scores relative to those with nociceptive-only pain, suggesting that using psychosocial pain surveys may be useful for understanding pain subtypes in patients with CP. Additional research is needed to identify biochemical and biophysical signatures that may associate with and predict responses to mechanism-specific interventions.
IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).
Richardson, Gary , Gutierrez, Martin , Kaumaya, Pravin T. P. , Phan, Tri, Chong, Leslie, Cha, Steven, Ede, Nicholas J. , Nixon, Bonnie , Good, Anthony J., Park, John , Boyer, Michael , Carbone, David Paul , Savvides, P. , Bekaii‐Saab, Tanios , Chong, Leslie Mi Ok

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e21134-e21134

10.1200/jco.2022.40.16_suppl.e21134 Get It

e21134 Background: Therapies with monoclonal antibodies targeting PD-1 and its ligands are associated with remarkable outcomes and have revolutionized cancer treatment (Honey 2017). However, patients treated with PD-1/PD-L1 blockade may develop “a primary or secondary resistance” to therapy (Sharma, Hu-Lieskovan et al. 2017). Contrary to monoclonal antibodies, chimeric B-cell cancer vaccines have the advantage of producing polyclonal B-cell antibodies that can potentially induce memory B- and T-cell responses, while reducing immune evasion and suppression. The hypothesis is that a polyclonal induced B-cell antibody response will be more effective or as effective with improved safety over current monoclonal antibody therapy. IMU-201 (PD1-Vaxx) is being developed using an active immunization approach to treat cancers that overexpress PD-L1 by inducing the production of anti-PD-1 antibodies with a peptide epitope designed to stimulate polyclonal antibodies against PD-1 (Kaumaya et al. 2020). Methods: The IMPRINTER study is an ongoing open-label dose escalation study of IMU-201 as monotherapy (Phase 1) or in combination with atezolizumab (Phase 1b) for patients with PD-L1 expressing non-small cell lung cancer (NSCLC). All patients enrolled in Phase 1 of the study must have previously received an immune checkpoint inhibitor and experienced disease progression. The primary objective is to evaluate the safety and tolerability of IMU-201 and identify the optimal biological dose (OBD). The secondary objective is to evaluate the efficacy of IMU-201 as monotherapy and in combination with atezolizumab. Humoral and cellular immunogenicity data will be evaluated, including IMU-201 and PD-1 specific antibodies (IgG, IgM), vaccine-specific cytokine levels, and regulatory and effector T and B cells. IMU-201 is administered by intramuscular (IM) injection on Day 1, Day 15, and Day 29. Dose-limiting toxicity (DLT) assessment is completed after 29 days on treatment. Tumor progression is evaluated according to RECIST 1.1 at Day 43 then every 42 days until progression or withdrawal. Results: In Phase 1, four patients were enrolled into each of the three cohorts at 10 μg/dose, 50 μg/dose and 100 μg/dose IMU-201 with no DLTs observed. In the 10 μg/dose cohort, one patient achieved CR and one patient SD; in the 50 μg/dose cohort, four patients achieved SD; and in the 100 μg/dose cohort, one patient achieved PR and two patients achieved SD. Within the 100 μg/dose cohort, one patient experienced an immune related pneumonitis after two IMU-201 administrations and discontinued from study treatment. Conclusions: IMU-201 had no observed DLT and demonstrated preliminary signs of efficacy. The study will therefore move into Phase 1b with IMU-201 being assessed in combination with atezolizumab. Clinical trial information: NCT04432207.